UCLA researchers reported a next‑generation CAR‑T design engineered to resist solid‑tumor immunosuppression and show activity in preclinical models, addressing a major barrier to CAR‑T efficacy outside hematologic cancers. The construct incorporates modifications intended to improve T‑cell persistence and tumor infiltration. Separately, investigators at the National University of Singapore identified protein tyrosine phosphatase 1B (PTP1B) as a modulator of immunogenic cell death that can increase tumor immunogenicity and synergize with existing immunotherapies. Both advances—cell engineering to overcome suppressive microenvironments and a druggable node to enhance immunogenic death—offer complementary strategies to broaden immunotherapy efficacy in solid tumors.